During the past decade, Nemocnica Poprad, a.s. conducted 2 clinical trials. In the 10-year time frame, 2 clinical trials started and 1 clinical trials were completed, i.e. on average, 50% percent of trials that started reached the finish line to date. In the past 5 years, 1 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

According to Clinical.Site data, the most researched conditions in "Nemocnica Poprad, a.s." are "Diabetic Retinopathy" (2 trials), "Diabetes Mellitus" (1 trials), "Hepatocellular Carcinoma" (1 trials) and "Macular Edema" (1 trials). Many other conditions were trialed in "Nemocnica Poprad, a.s." in a lesser frequency.

Most popular intervention types in "Nemocnica Poprad, a.s." are "Drug" (3 trials) and "Other" (2 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (2 trials), "Axitinib (AG-013736)" (1 trials), "Best Supportive Care" (1 trials), "Ranibizumab 0.5mg" (1 trials) and "Runcaciguat (BAY1101042)" (1 trials). Other intervention names were less common.

The vast majority of trials in "Nemocnica Poprad, a.s." are 3 trials for "All" genders.

Currently, there are NaN active trials in "Nemocnica Poprad, a.s.". undefined are not yet recruiting, 1 are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 2 completed trials in Nemocnica Poprad, a.s., undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Nemocnica Poprad, a.s., 0 "Phase 1" clinical trials were conducted, 3 "Phase 2" clinical trials and 0 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".